Freedom Holdings, Inc. announce following Company Update: Freedom Holdings waiting on 15c211 final approval from FINRA. This past summer, Freedom Holdings had worked diligently with a Glendale Securities over the past several months to seek FINRA approval of its 15C-211. Glendale Securities, to file it's 15c211 with FINRA.

After answering all FINRA's comments, Freedom Holdings nears final approval of its 15c211 to bring the company from current audited fully reporting Pink Sheet, to OTCQB. The past couple of months, the company has been in talks with institutions and investors who have shown interest in making an investment in Freedom Holdings. As the new year approaches, the company plans to purchase a new facility to Extract, Manufacture, Grow and Test all cannabis products within own Facility.

The Company's medical cannabis, division (MCD), expects to begin the FDA - Clinical Trials to treat cancer Pain in mid-February. Based on the fact 100's of companies have started clinical trials for cannabis, phase one "safety" is already done and registered. This gives Freedom Holdings a clear advantage for an early and quicker completion.